MedTrace Logo

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00003008 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2023-06-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with AIDS-related Kaposi's sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

indinavir sulfate

DRUG

nelfinavir mesylate

DRUG

paclitaxel

DRUG

ritonavir

DRUG

saquinavir mesylate

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • AIDS Associated Malignancies Clinical Trials Consortium

    collaborator OTHER

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Jamie Hayden Von Roenn, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-12-15
Primary Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003008 on ClinicalTrials.gov